BACKGROUND: Trauma-induced coagulopathy occurs in about 25% of injured patients and accounts for about 10% of deaths worldwide. Upon injury, hemostatic function may decline due to vascular dysfunction, clotting factor deficiencies, hyperfibrinolysis, and/or platelet dysfunction. We investigated agonist-induced calcium signaling in platelets obtained over time from trauma patients.
T raumatic injuries are one of the most common causes of death in the United States and abroad, accounting for about 10% of fatalities worldwide. 1 Trauma is well recognized as the leading cause of death for younger populations (persons aged 30-40 years).
1,2 Upon admission to trauma centers for a wide range of mechanisms of injury, approximately 25% of patients will present with a condition known as trauma-induced coagulopathy, 1, 3 a complex clinical state highlighted by impaired activity of important blood clotting proteins, excessive fibrinolysis, and significant platelet dysfunction. 1 The intersection of these phenomena tends to lead to a coagulopathic bleeding phenotype which becomes difficult to treat and increases the chance of mortality by more than fourfold. 4 Several events may combine to drive trauma-induced coagulopathy. For example, perturbation of the endothelium during a response to a traumatic episode can lead to generation of activated protein C and glycocalyx shedding, both of which serve anticoagulant and profibrinolytic roles. 1 Other biochemical changes also occur in concert with hemorrhagic shock, including release of tissue factor (TF) and tissue plasminogen activator, which lead to thrombin and plasmin generation in the circulation. 2, 5, 6 The coinciding coagulant and lytic processes are responsible for elevated levels of soluble fibrin species, which have traditionally been quantified by plasma levels of fibrin degradation products, such as D-dimer. [7] [8] [9] [10] However, the full extent and mechanisms of acquired platelet dysfunction remain poorly understood.
Platelet dysfunction in trauma patients has been reported in several studies through the use of traditional assays like aggregometry, thromboelastography (TEG), and microfludics. [11] [12] [13] [14] Key findings include decreased aggregation responses to an array of platelet agonists in about half of the tested subjects, 12 80% inhibition of adenosine 5′-diphosphate sodium salt (ADP)-induced platelet function, 13 and defects in deposition to collagen under flow in two thirds of the patient cohort. 14 The concept of an "exhausted" platelet arises from initial hyperstimulation in response to tissue damage and eventual tiring of the cell as it continues in circulation. 13 Proteolysis or internalization of platelet receptors, including glycoproteins VI (GPVI) or Ib (GPIb), might also play a role in downregulation of platelet function. 15 Soluble fibrin has been shown to cause a signaling defect in GPVI, 16 possibly contributing to impaired initial platelet adhesion to exposed collagen at the site of vascular injury if platelets interact with circulating fibrin species prior to encountering a wound site in need of hemostatic response.
Studies of platelets from trauma patients have typically only used one or two major agonists. With technologies for high dimensional phenotyping of calcium signaling pathways, building patient-specific phenotypic profiles of blood cell function may provide more information for treatment decisions. This work focuses on assessing platelet function in trauma patients using a high-throughput technique to interrogate up to six platelet signaling pathways via combinatorial stimulation of surface receptors and using intracellular calcium mobilization as a dynamic readout. Additionally, we investigated platelet dysfunction during trauma by examining the effects of trauma patient plasma on healthy platelets. By all metrics, platelets from trauma patients frequently display a defect in agonist response and the plasma from trauma patients may influence this dysfunctional platelet phenotype.
METHODS

Reagents
Apixaban (SelleckChem, Houston, TX), D-phenylalanylprolyl-arginyl chloromethylketone (PPACK; Essex Junction, VT), ADP, prostaglandin E 1 , citrate concentrated solution, and apyrase (Sigma-Aldrich, St. Louis, MO), the GPVI agonist convulxin (Cayman Chemical, Ann Arbor, MI), the TP agonist U46619, the IP agonist iloprost (Tocris Bioscience, Bristol, UK), the PAR4 agonist peptide H-Ala-Tyr-Pro-Gly-Lys-Phe-NH 2 trifluoroacetate salt (AYPGKF) and the PAR1 agonist peptide H-Ser-Phe-Leu-Leu-Arg-Asn-OH trifluoroacetate salt (SFLLRN) (Bachem, Torrance, CA), Fluo-4 NW calcium dye and probenecid (Invitrogen, Carlsbad, CA), and FITC mouse anti-human PAC-1, PE mouse anti-human CD62P, and Cy5 Annexin V fluorescent antibodies (BD Biosciences, San Jose, CA) were used and stored according to manufacturers' instructions. HEPES-buffered saline (HBS, pH 7.4) was prepared with 20 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES, Fisher Scientific, Fair Lawn, NJ, USA) and 150 mM NaCl (Fisher); Tyrode's buffer (pH 7.4) was prepared with 10 mM HEPES, 127.2 mM NaCl, 11.9 mM NaHCO 3 (Fisher), 5 mM KCl (Fisher), 0.4 mM NaH 2 PO 4 (Fisher), 1 mM MgCl 2 ·6 H 2 O (Sigma), and 5 mM D-glucose (Sigma). Where specified, Ca 2+ HBS was prepared by dissolving CaCl 2 ·2 H 2 O in HBS to achieve a calcium concentration of 2 mM.
Study Design
Under institutional review board approval, blood was obtained from trauma patients (n = 16) who had been admitted to the Penn Presbyterian Medical Center Level 1 Trauma Center following a severe injury. Patients who are 18 years or older, present as a trauma alert, and are admitted to the Trauma and Surgical Intensive Care Unit were eligible for the study. Upon arrival to the trauma bay, a research blood sample (15 mL) and clinical data were collected by Penn Acute Research Collaboration (PARC) research staff. The legal authorized representative and/or patient is consented once available and after being debriefed by the clinical care team. Descriptions of patient demographics and clinical presentations are outlined in Table 1 .
For each enrolled patient, blood samples were taken at specific time points (0, 3, 6, 12, 24, 48 , and 120 hours) after initial admission. Several aliquots with specific anticoagulants were prepared for various clinical tests according to the previously established protocol; one such tube preloaded with apixaban (1.25 μM, final concentration) and PPACK (100 μM, final concentration) was prepared for the studies in this article. Collecting blood (2 mL) into two anticoagulants ensured inhibition of factor Xa-mediated thrombin generation and thrombin activity, respectively. The sample was split into two microcentrifuge tubes to isolate platelet-rich plasma (PRP) for immediate platelet function studies and platelet-poor plasma (PPP) to be frozen for future analysis.
In addition to the patient cohort, a set of healthy donors (n = 11) was recruited to donate blood according to University of Pennsylvania Institutional Review Board approval. Donors self-reported to being free of any medication or alcohol use for 3 days leading up to the blood draw. Additionally, female donors self-reported to not using oral contraceptives.
Intracellular Calcium Mobilization Assays
Platelet calcium measurements were conducted using a 384-well plate format as previously described. 16 Briefly, PRP was prepared via centrifugation of whole blood (120 g, 10 minutes) and incubated with Fluo-4 NW calcium dye for 30 minutes. The dye was reconstituted with 5 mL HBS and 200 μL probenecid (77 mg/mL) to prevent dye leakage from cells during incubation. One 384-well plate was filled with dilute, dye-loaded PRP (12% final concentration after agonist dispense), while a second plate was prepared with platelet agonists at specified concentrations. Using the pairwise agonist scanning method as motivation, 17, 19 an array of combinatorial stimuli (platelet agonists/antagonists) was used to develop subject-specific phenotypic profiles of platelet activity. As reported previously, pairwise agonist scanning involves exposing dilute PRP to all single and pairwise combinations of up to six stimuli at low, medium, and high concentrations, resulting in 154 unique conditions. To complete two replicates/condition, approximately 15 mL to 20 mL of whole blood is required to isolate the necessary amount of PRP. However, due to volume constraints in the protocol (2 mL whole blood per patient sample), the combinatorial space was restricted to 31 unique conditions-single combinations of five agonists (ADP, EC 50 = 1 μM; U46619, EC 50 = 1 μM; convulxin, EC 50 = 2 nM; SFLLRN, EC 50 = 10 μM; and AYPGKF, EC 50 = 300 μM) at three dosage levels each (0.1Â, 1Â, 10ÂEC 50 ), and pairwise combinations of the same five agonists as well as one antagonist (iloprost, EC 50 = 0.2 μM) with each component present at a medium dose (1ÂEC 50 ) (Fig. S1 , Supplemental Digital Content 1, http://links.lww.com/TA/B251). The two well plates were then inserted into a FlexStation 3 automated plate reader (Molecular Devices, Sunnyvale, CA) and liquid handling functions were used to dispense 20 μL of agonist(s) directly into each well of 30 μL PRP. The fluorescence of the plate was read columnwise (Ex, 485 nm; Em, 525 nm) for 20 seconds prior to dispense and then for an additional 4 minutes; the dynamic signal F(t) was also normalized to the predispense baseline F o . As a metric of each platelet sample, the amount of calcium mobilized for all stimuli can be calculated as the total platelet calcium mobilization (TPCM) by Eq. (1):
where AUC is the area under the curve for calcium trace obtained for the ith condition.
Flow Cytometry Assays
Monitoring platelet activation via flow cytometry was conducted as documented previously. 20 In short, PRP was isolated as described above and diluted to 10% v/v with Ca 2+ HBS. In each test tube, 10 μL dilute PRP was added to 74 μL Ca 2+ HBS and 2 μL each of three fluorescently labeled antibodies (FITC anti-PAC-1 for α 2b β 3 activation, PE anti-CD62P for P-selectin expression, and Cy5 Annexin V for PS exposure). Prior to analysis, 10 μL of platelet agonists were added to the tubes and allowed to incubate in the dark for 10 minutes. Each sample was analyzed using an Accuri C6 Plus flow cytometer (BD Biosciences), setting the flow rate to low (14 μL/min, 10 μm core) and reading for 60 seconds. Data were collected and reported as mean fluorescence intensity for activated α 2b β 3 and P-selectin, or % PS-positive cells as determined by preset gating techniques.
Washed Platelet Preparation for Plasma Reconstitution Experiments
Plasma samples were collected from healthy/patient whole blood and stored at −80°C for future analysis. Healthy washed platelets (WP) were prepared fresh following standard procedures. Specifically, whole blood was drawn into syringes containing citrate concentrated solution (4% w/v) in a 1:9 citrate-whole blood ratio and apixaban (1.25 μM). Platelet-rich plasma was isolated as described above, incubated in calcium dye for 30 minutes, and recalcified with 2 mM CaCl 2 . The PRP mixture was diluted into Tyrode's buffer supplemented with 1 μM prostaglandin E 1 and 1 U/mL apyrase prior to further centrifugation (1200 g, 14 minutes). The supernatant was removed and the resulting platelet pellet was resuspended in Ca 2+ HBS. Washed platelets were combined with plasma samples at specified volume fractions and incubated for approximately 30 minutes before platelet function challenge with various agonists (Fig. S2 , Supplemental Digital Content 1, http://links.lww.com/TA/B251). For example, a final plasma concentration of 12% is achieved by addition of 6 μL PPP to 24 μL WP and 20 μL agonist. Calcium mobilization measurements were recorded following the same procedure detailed in the previous section.
Thromboelastography
Blood samples were collected on arrival to the trauma bay (T0), and at 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 120 hours and immediately aliquoted into tubes containing distinct anticoagulants for assessment of platelet function or hemostasis state using the TEG 6s Hemostasis system (Haemonetics Corp., Braintree, MA) as per the manufacturer's instructions. To monitor the kinetics of patient blood clotting, 1 mL of blood was mixed with 15.87 units of heparin (Sagent Pharmaceuticals, Schaumburg, IL) and was pipetted into the PlateletMapping ADP cartridge (Haemonetics, 07-615-US). Separately, whole blood was anticoagulated in 3.2% buffered sodium citrate (BD Vacutainer, Becton, Dickson & Co., Franklin Lakes, NJ) and pipetted into the Citrated Multichannel Cartridge (Haemonetics, 07-601-US) which provides clotting characteristics data simultaneously from four independent assays. The deidentified data were stored in a secure server.
Statistical Analysis
Analysis of raw calcium fluorescence data were performed by MATLAB version R2016a (MathWorks, Natick, MA). Statistical significance tests of results based on experimental condition were conducted using a two-tailed unpaired Student's t test in Prism version 5.03 (GraphPad Software, San Diego, CA). Verni et al.
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RESULTS
Calcium Mobilization Measurements Indicate Global Platelet Dysfunction in Trauma Patients
A total of 31 blank, single, and pairwise mixtures of platelet agonists were prepared as shown in the color-coded concentration map (Fig. 1A) where each row corresponds to a specific input agonist mixture (dark blue, no agonist; light blue, low concentration; yellow, medium concentration; red, high concentration). Each stimulation condition yields a normalized calcium trace [F(t)/F o ] and all 31 traces are shown as 31 rows in a heatmap (Fig. 1B-C) . Comparison of the platelets from healthy donors (Fig. 1B) and trauma patients (Fig. 1C) demonstrates a markedly dysfunctional phenotype in the trauma patient platelets across all types of agonist stimuli. While trauma platelets responded best to the highest dose of convulxin, this response was greatly attenuated compared to healthy platelets. Overall, the healthy donor pool exhibited a significantly greater extent of TPCM than the trauma patient cohort (Fig. 1D-E) . The average TPCM for healthy platelets was 220 ± 62 a.u. (Fig. 1D) , greater than that found for every trauma patient at the initial time point of the test 0-hour TPCM (Fig. 1E) . Total platelet calcium mobilization was depressed for every patient in blood samples tested between 0 hours and 12 hours. In general, TPCM displayed an increasing trend with time in several patients, but only four patients (patients 014, 019, 020, 038) had a single reading in the healthy range at times between 12 hours and 120 hours, potentially due to platelet transfusion.
Trauma Patient Platelets Exhibit Decreased α 2b β 3 Activation, P-Selectin Expression, and Phosphatidylserine Exposure Upon Stimulation in Flow Cytometry
Beyond calcium mobilization, platelet activation also can drive integrin activation, granule release and phosphatidylserine exposure (especially with collagen/thrombin stimulation). Fluorescently activated α 2b β 3 antibody, P-selectin antibody, and annexin V were used in a flow cytometry assay to measure platelet activation in the healthy and patient cohorts. Dilute (1%) PRP was stimulated with calcium-containing HBS, ADP (2 μM), or convulxin (4 nM). Unstimulated trauma platelets displayed low levels of activated α 2b β 3 , P-selectin, and PS, indicating that they were not in a classically "activated" state at the start of the assay. The trauma platelets, however, were able to display stimulated levels of α 2b β 3 , P-selectin, and PS, but to an extent much lower than that seen with healthy platelets ( Fig. 2A-C) . As was observed in the calcium mobilization assay, addition of convulxin caused the greatest response in both healthy subjects and trauma patients. Significant PS exposure was only observed in healthy donors when subjected to convulxin; the other data showed no detectable difference above the buffer control response (Fig. 2C) . A representative set of results for a healthy donor is shown in Figure S3 , Supplemental Digital Content 1, http://links.lww.com/TA/B251.
TEG Data Reveal Patient Platelet Defects in Whole-blood Samples
Whole blood samples from trauma patients were anticoagulated with sodium citrate or heparin and dispensed into TEG cartridges to measure platelet function and/or hemostatic state. For each test using citrated blood, the machine generates an output of five parameters describing different aspects of the clot formation process: the time to initial fibrin formation (R), the time to achieve a certain level of clot strength (K), the rate of clot generation (angle), the strongest point of fibrin clot (MA), and the extent of fibrinolysis 30 minutes after achieving MA (LY30). Using the RapidTEG reagent to interrogate both the intrinsic and extrinsic coagulation pathways with kaolin and TF, respectively, patient blood samples exhibit relatively accelerated coagulation characteristics, namely, clotting times and rates, with little to no observed lysis (Fig. 3A-D) . However, platelet-driven clot development and strength appear to be diminished during the first 6 hours posttrauma, as suggested by the MA parameter (Fig. 3E) , typically most indicative of platelet function. 21 Further, ADP stimulation of heparinized whole blood reveals a distinct platelet aggregation defect on par with the results from calcium mobilization and flow cytometry experiments (Fig. 3F) .
Healthy Human Platelets Exhibit Impaired Function in Plasma From Trauma Patients
Freshly prepared WPs reconstituted with plasma (12% v/v plasma, final concentration) were challenged with agonists at high doses (10ÂEC 50 ). Responses to convulxin, ADP, U46619, and SFLLRN were significantly reduced when platelets were in the presence of plasma isolated from trauma patient blood samples (Fig. 4A-D) . Specifically, the signals were 54%, 56%, 59%, and 54% lower in terms of AUC when the system contained patient plasma compared to healthy plasma. These data indicate a clear role for a plasma component on platelet function, perhaps polymerized fibrin or its degradation products as suggested in other work. 16, 22, 23 ELISA for D-dimer, the smallest fibrin degradation product (FDP) in Figure 2 . Trauma patient samples show impaired integrin α 2b β 3 activation, P-selectin expression, and phosphatidylserine exposure in flow cytometry. Fluorescence-activated cell sorting (FACS) was used to detect platelet activation following stimulation with ADP (2 μM), convulxin (4 nM), or buffer. Fluorescent antibodies against the activated form of integrin α 2b β 3 (A), P-selectin (B), and exposed phosphatidylserine (C) were incubated with dilute PRP (1% final concentration) prior to agonist stimulation. Conditions were tested in replicate for each donor/patient and mean fluorescent intensities of each peak were calculated. For PS exposure, the percentage of positive cells was determined by the relative intensity of the second peak after gating the data.
terms of size, showed~30-fold increase in D-dimer concentration in trauma patient plasma in comparison to healthy plasma (Fig. S4 , Supplemental Digital Content 1, http://links.lww.com/TA/B251). The patient and healthy plasma samples used in the experiment shown in Figure 4 contained 21.9 nM and less than 1 nM D-dimer, respectively.
Healthy Plasma Imparts a Detectable Inhibition of WP Activation But Patient Plasma Samples Result in More Potent Effect
The previous experiment was repeated with a screen of plasma samples from several healthy donors and trauma patients to detect the range of effects of each class of plasma. TEG results for patient samples over time. Five important parameters describing clot formation and strength were measured at different timepoints using a TEG 6s Hemostasis System (A-E). Averaged data for trauma patients (n = 14) are shown for citrated whole blood treated with RapidTEG reagent (dried kaolin + TF) and CaCl 2 for recalcification. The reported normal ranges (shaded) are: R = 4-8 minutes; K = 1-4 minutes; angle = 47-74°; MA/max amplitude = 55-73 mm; LY30 = 0-8%. Additionally, platelet function was measured using the compatible PlateletMapping cartridge. Data were collected using heparinized whole blood and the final metric of platelet activation was calculated as percent aggregation in response to ADP stimulation (F), where the shaded region indicates the reference range (83-100%).
A control condition (no plasma addition) served as a baseline response to which wells containing healthy or trauma plasma were normalized. High concentrations of convulxin (20 nM) or ADP (10 μM) were used as challenging stimuli and the calcium mobilization AUC result for each platelet/ plasma pair are plotted as percent of the control response (Fig. 5A-B) . In the case of each stimulating agonist, the presence of healthy plasma resulted in~25% reduction of the control response, whereas addition of patient plasma samples further decreased the observed signal to~50% on average. Each data set shows statistical significance from the others, with the difference between the control condition and the trauma plasma samples being the most significant for both agonists.
Plasma Concentration Is Correlated With Decreased Platelet Function
All platelet-plasma combination experiments in previous sections were comprised of 12% plasma and a clear downregulatory effect was observed. The effect of final plasma content was studied by titrating a range of concentrations (1-30%) and challenging platelet function with 20 nM convulxin, 100 μM SFLLRN, or 10 μM ADP. For each of the agonists, a negatively sloping dose-response curve was created in which platelets incubated in increasing levels of healthy donor-derived or trauma patient-derived plasma steadily became hypofunctional (Fig. 6A-C) . The negative correlation between platelet calcium mobilization and plasma concentration was evident in both healthy and patient plasma settings, though there was clear parity between the two plasma classes at each concentration to an extent comparable to the results in Figures 4 and 5 .
DISCUSSION
In an effort to better understand platelet dysfunction in trauma patients, we present new results confirming the phenotype in several functional assays. Combinatorial agonist stimulation revealed significant depression of platelet calcium mobilization in patient samples compared to healthy controls, though it appeared the two populations show similar Figure 4 . Healthy donor platelets lose function when reconstituted in trauma patient-derived plasma. WPs from healthy donors were prepared according to standard protocol and resuspended in PPP from healthy donors or trauma patients. The platelet-plasma systems were incubated for about 10 minutes before exposure to various platelet agonists to test cell functionality. The agonists tested were 20 nM convulxin (A), 10 μM ADP (B), 10 μM U46619 (C), and 100 μM SFLLRN (D). In each case, platelets in a trauma plasma setting showed~50% decrease in calcium mobilization from platelets in a healthy plasma setting.
sensitivity to strong agonist conditions (e.g. high dose CVX) (Fig. 1) . Patient responses varied widely, perhaps due to diverse injury conditions or treatment strategies, and partial recovery of platelet function was observed in one-third of the patients. Trauma patients also showed low α 2b β 3 activation, P-selectin display, and PS exposure following stimulation via flow cytometry (Fig. 2) , and TEG data showed relatively fast clotting times (R, K) and rates of clot formation (angle), but initially diminished clot development (MA) and platelet aggregation (Fig. 3) . The patient sample size in this study (n = 16) may prevent the generalizable nature of the results and certainly warrants further investigation, but we have validated the coagulopathic phenotype of platelet dysfunction through the use of several lab and clinical techniques, which has not been reported previously to our knowledge.
A potential link between these results is the injury severity score (ISS), an anatomical quantification system to describe the extremity of a patient's injured state. The ISS accounts for multiple regions of the body, with scores ranging from 0 to 75 and the threshold for major trauma set at ISS = 15. 24, 25 Individual ISS scores for the cohort of 16 trauma patients are listed in Table 1 (median = 24.5, IQR = 15). This large range led us to hypothesize that the extent of platelet dysfunction may be correlated with the severity of the condition. However, we found no such relationship (Fig. S5 , Supplemental Digital Content 1, http://links.lww.com/TA/B251), suggesting an added emphasis on the plasma effect observed in Figures 4-6 . The final ISS assigned to a patient is often determined at some later time point during or even after the patient's stay and does not account for the patient's previous medical history, which may explain the lack of correlation.
We also show a negative influence of plasma on platelet function. Diluting PRP with PPP to normalize platelet count has previously been shown to impair platelet aggregation. 26 Further, cellular microparticles isolated from traumatic hemothorax blood, and to a lesser extent shed frozen plasma, inhibit platelet response to ADP, arachidonic acid, and collagen. 27 The effect we observed was more potent with trauma patient-derived plasma, implying an amplified role of certain soluble species on cell viability. Other groups have shown elevated levels of soluble FDPs in trauma patient plasma, 9,10 which we confirmed via D-dimer ELISA (Fig. S4 , Supplemental Digital Content 1, http://links. lww.com/TA/B251). The role of circulating fibrin fragments on inherent and transfused platelet function is a subject of continuing study, but initial results show binding sites for fibrin on GPVI 23 and signaling defects following thrombinmediated platelet activation and fibrin polymerization. 16 At this point, it is difficult to elucidate whether these species (e.g. D-dimer) are meant to simply serve as a biomarker or if there exists an important mechanistic explanation linking elevated plasma concentrations and platelet dysfunction. Other possible hypotheses include roles of platelet-silencing species such as cAMP and cGMP, which are reported as elevated in trauma platelets and correlated with injury severity. 28 With the sustained prevalence and diversity of traumarelated injuries and mortalities, understanding the mechanisms of action as well as developing sufficient treatment strategies is becoming increasingly necessary. We highlighted the development of phenotypic profiles of platelet function to be used to guide clinicians in making informed decisions. Additionally, the observation of a plasma-mediated inhibitory effect gives rise to implications of transfusion therapies being ineffective or Figure 5 . Screening several plasma samples reveals a more potent inhibitory effect in trauma samples than healthy samples. Functionality of platelets from healthy donors (n = 3-4) was screened in the presence and absence of PPP from several other healthy donors and trauma patients using the same protocol as Fig. 4 . Responses to 20 nM convulxin (A) and 10 μM ADP (B) were normalized to the control condition (no plasma). Though healthy plasma showed a downregulation of platelet function, plasma derived from trauma patients showed a more potent inhibition in both agonist tests. Data are presented as mean ± SEM. (**p < 0.01, ***p < 0.001, ****p < 0.0001).
uninformed. Recent work has debated the appropriate volumes and ratios of blood products to administer to coagulopathic patients, 29, 30 but perhaps transfusions are not always optimal. In fact, platelet transfusions in trauma patients have been shown to have little effect on platelet function recovery 31 and resuscitation of hemorrhagic rats via whole blood delivery failed to restore platelet viability. 32 Healthy platelets may inherit the "zombie" nature of the unresponsive but still circulating cells upon exposure to the patient's plasma, as suggested by the in vitro results in this study. Figure 6 . Increasing plasma concentrations reduces the calcium fluorescent signal in both healthy and patient plasma settings. Plasma concentration was varied from 1% to 30% and healthy WPs were incubated in the presence of healthy (autologous/nonautologous) plasma or trauma plasma. A control response (no plasma) was also prepared for data normalization purposes. All conditions were challenged with a potent dose of convulxin (20 nM) , and data were plotted as a dose-response curve showing a negative relationship between plasma concentration and platelet response. Data are presented as mean ± SD.
